December 2023 saw FDA approve first gene therapies for sickle cell—Bluebird Bio’s Lyfgenia and CRISPR/Vertex’s Casgevy—ushering in a transformative treatment era . https://www.datamintelligence.com/research-report/sickle-cell-disease-treatment-market